Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Maxim Group Downgrades VistaGen Therapeutics to Hold

Maxim Group analyst Jason McCarthy downgrades VistaGen Therapeutics (NASDAQ:VTGN) from Buy to Hold.
byBenzinga Newsdesk
July 26, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Maxim Group analyst Jason McCarthy downgrades VistaGen Therapeutics (NASDAQ:VTGN) from Buy to Hold.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Apple Taps Seasoned Executive To Head ‘Secret’ Team Developing Glucose Monitoring Device – Stocks To Watch

By Vandana Singh
September 15, 1:46 PM
Apple Inc (NASDAQ: AAPL) has appointed Tim Millet, a seasoned executive with a background in iPhone and Mac chip technology, to oversee its secretive team dedicated to developing a noninvasive blood sugar monitor, signaling a significant move in the company's health technology endeavors. 

AAPL